Guggenheim lowered the firm’s price target on Immunovant (IMVT) to $44 from $46 and keeps a Buy rating on the shares after having hosted management for an investors lunch and discussed expectations for the upcoming batoclimab readouts, as well as the company’s development strategy for their next-gen potentially best-in-class anti-FcRn ‘1402. The firm has updated its model for fiscal Q3, the analyst noted.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMVT:
- Immunovant’s Strategic Positioning and Financial Strength Propel IMVT-1402 Towards Pivotal Studies
- Immunovant management to meet with Piper Sandler
- Immunovant Reports Progress Amid Increased R&D Costs
- Immunovant’s Promising Pipeline and Strategic Advancements Reinforce Buy Recommendation
- Immunovant reports Q3 EPS (76c), consensus (75c)